SNWVHealthcare · Medical DevicesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 10 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores SANUWAVE Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (100): The business earns solid, repeatable profits on what it owns.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SNWV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 Mar 2026 | Roth Capital | Reiterates | Buy | $53 → $47 |
| 3 Sept 2025 | Northland Capital Markets | Initiates | Outperform | — |
| 22 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 29 July 2025 | Roth Capital | Initiates | Buy | — |
| 15 Sept 2020 | Lake Street | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNWV appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, SANUWAVE Health, Inc. returned −88.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 66% of US stocks
Cheaper than 74% of US stocks
Cheaper than 5% of US stocks
Cheaper than 34% of US stocks
Higher than 22% of US stocks
Higher than 31% of US stocks
Higher than 88% of US stocks
Higher than 30% of US stocks
Higher than 92% of US stocks
Higher than 99% of US stocks
Higher than 79% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
SANUWAVE Health, Inc. has a market value of $34.4M and an enterprise value of $45.7M.
Revenue in the twelve months to 30 June 2026: $43.9M. The latest quarter shrank 3.1% year on year.
Net income over the same four quarters: $14.3M, a 32.6% net margin.
Free cash flow in the twelve months to 30 June 2026: $4.0M.
Trailing P/E: 4.9×; forward P/E: −400.0× — the forward figure prices analyst consensus estimates, not reported earnings.
SANUWAVE Health, Inc. employs 55 people — $798K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own SANUWAVE Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published the transcript of SANUWAVE Health, Inc.'s Q2 2026 earnings call, following the company's presentation of its quarterly results and commentary to investors.
Why it matters — The Q2 2026 earnings call transcript offers SNWV watchers direct access to management's discussion of the company's recent performance and outlook.
Sanuwave Health reported Q2 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier. The decline was driven by lower UltraMIST system sales, which offset continued growth in the company's recurring applicator business.
Why it matters — A revenue decline despite growth in the recurring applicator segment highlights ongoing challenges in the company's product mix and top-line performance.
Sanuwave announced its Q2 FY2026 financial results, reporting revenues of $9.7 million, down 3% from $10.1 million in Q2 2025. Gross margin for the quarter was 76.2%, compared to 78.1% in the prior-year quarter.
Why it matters — These results provide the latest revenue and profitability figures for Sanuwave, showing a slight year-over-year decline in both revenue and gross margin that SNWV watchers would track.
Sanuwave Health, Inc. announced it will host a conference call on August 7, 2026, at 8:30 AM ET to present its second-quarter 2026 financial results.
Why it matters — The call will provide investors and stakeholders with the company's latest quarterly financial performance and business update.
Of the 1 analysts covering SANUWAVE Health, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SANUWAVE Health, Inc. 54 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Sept 2026, SANUWAVE Health, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).
No analyst covering SANUWAVE Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNWV are extrapolating price history, which says nothing about the business.
SANUWAVE Health, Inc. returned -88.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
SANUWAVE Health, Inc. Common Stock represents a medical device company focused on noninvasive energy-based therapies for wound care and regenerative healing.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "SANUWAVE Health, Inc. (SNWV) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of SANUWAVE Health, Inc.'s Q2 2026 earnings call, following the company's presentation of its quarterly results and commentary to investors.
SANUWAVE Health, Inc. Common Stock represents a medical device company focused on noninvasive energy-based therapies for wound care and regenerative healing. SANUWAVE develops and markets ultrasound and shockwave systems designed to support the treatment of acute and chronic wounds, with its UltraMIST platform serving as a key commercial product. The company also works in related areas such as tissue, musculoskeletal, and vascular repair, positioning its technologies within advanced wound management and regenerative medicine. Its business is centered on designing and selling medical devices to healthcare providers, with products used in clinical settings that require targeted, non-contact therapeutic solutions. SANUWAVE Health, Inc. Common Stock is associated with a healthcare technology business that addresses specialized treatment needs across wound care and tissue recovery markets.
CEO Mr. Morgan C. Frank · 55 employees · United States · https://sanuwave.com
